MOLOGNI, LUCA

MOLOGNI, LUCA  

DIPARTIMENTO DI MEDICINA E CHIRURGIA (SCHOOL OF MEDICINE AND SURGERY)  

Mostra records
Risultati 1 - 20 di 86 (tempo di esecuzione: 0.043 secondi).
Titolo Tipologia Data di pubblicazione Autori File
DNA Damage Response (DDR) Is Associated With Treatment-free Remission in Chronic Myeloid Leukemia Patients 01 - Articolo su rivista 2023 Malighetti, FedericaMauri, MarioManghisi, BeatriceInzoli, ElenaRindone, GiovanniCivettini, IvanGuglielmana, VeronicaRamazzotti, DanieleBombelli, SilviaPerego, RobertoPiazza, RoccoMologni, LucaGambacorti-Passerini, Carlo +
Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma 01 - Articolo su rivista 2022 Mologni L.Gambacorti Passerini C. +
Dual kinase targeting in leukemia 01 - Articolo su rivista 2021 Mologni L.Redaelli S. +
New advances in liquid biopsy technologies for anaplastic lymphoma kinase (Alk)—positive cancer 01 - Articolo su rivista 2021 Villa M.Sharma G. G.Manfroni C.Cortinovis D.Mologni L.
Synergistic drug combinations prevent resistance in ALK+ anaplastic large cell lymphoma 01 - Articolo su rivista 2021 Sharma, GGVilla, MMauri, MCrespiatico, IFontana, DMastini, CMagistroni, VCeccon, MRedaelli, SMassimino, LPiazza, RGambacorti Passerini, CMologni, L +
SETBP1 accumulation induces P53 inhibition and genotoxic stress in neural progenitors underlying neurodegeneration in Schinzel-Giedion syndrome 01 - Articolo su rivista 2021 Massimino L.Di Resta C.Piazza R.Mologni L. +
STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma 01 - Articolo su rivista 2021 Sharma G. G.Mologni L.Gambacorti Passerini C. +
Whole exome sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target 01 - Articolo su rivista 2021 Ceccon M.Mologni L.Gambacorti Passerini C. +
Integrated Genomic, Functional, and Prognostic Characterization of Atypical Chronic Myeloid Leukemia 01 - Articolo su rivista 2020 Fontana, DilettaRamazzotti, DanieleAroldi, AndreaRedaelli, SaraMagistroni, VeraPirola, AlessandraMassimino, LucaMastini, CristinaBombelli, SilviaElli, Elena MariaFumagalli, MonicaPerego, Roberto APagni, FabioMologni, LucaPiazza, RoccoGambacorti-Passerini, Carlo +
IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma 01 - Articolo su rivista 2020 Sharma G. G.Gambacorti Passerini C.Mologni L. +
An Imatinib–non-responsive patient with an ABL Leu387Trp mutation achieves cytogenetic and molecular response under bosutinib: Case report and biological characterization 01 - Articolo su rivista 2020 Crespiatico, IlariaBossi, ElisaPiazza, RoccoMologni, LucaGambacorti‐Passerini, Carlo +
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy 01 - Articolo su rivista 2020 Bossi E.Aroldi A.Steidl C.Verga L.Fontana D.Sharma G. G.Mologni L.Piazza R.Gambacorti Passerini C. +
We shall overcome (drug resistance) some day 01 - Articolo su rivista 2019 Geeta, GeetaMologni, Luca
A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib 01 - Articolo su rivista 2019 Sharma G. G.Cortinovis D.Villa M.Cordani N.Bidoli P.Pagni F.Piazza R.Gambacorti-Passerini C.Mologni L. +
Phase ii study with crizotinib in patients with anaplastic lymphoma kinase (alk)-positive lymphoma relapsed/refractory to chemotherapy 02 - Intervento a convegno 2019 Bossi ESteidl CFontana DSharma GGMologni LPiazza RGGambacorti Passerini C +
Wiskott–Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma 01 - Articolo su rivista 2019 Sharma, Geeta GeetaMastini, CristinaMologni, LucaGambacorti-Passerini, Carlo +
Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes 01 - Articolo su rivista 2018 Sharma, GGMologni, LGambacorti-Passerini, C +
Abstract 902: In vitro andin vivocharacterization of resistance to lorlatinib treatment in ALK mutated cancers 02 - Intervento a convegno 2018 GEETA, GEETARedaelli, SCeccon, MGambacorti-Passerini, CMologni, L +
β-catenin knockdown promotes NHERF1-mediated survival of colorectal cancer cells: Implications for a double-targeted therapy 01 - Articolo su rivista 2018 Mologni, LucaGIANNI, STEFANOPasserini, Carlo Gambacorti +
Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling 01 - Articolo su rivista 2018 Ceccon, MonicaMauri, MarioMassimino, LucaPiazza, RoccoGambacorti-Passerini, CarloMologni, Luca +